People often argue that the FDA is too restrictive,” said Roger Perlmutter, head of research and development at Merck & Co Inc. “We have the sense that the balance is pretty right you have to have a well-characterized risk/benefit profile.” That stance underscores the unique position the drug industry finds itself in when it comes to regulating its products.